| scholarly article | Q13442814 |
| P50 | author | Jerome I Rotter | Q59813011 |
| Kent D Taylor | Q89467237 | ||
| Yen-Chu Chen | Q98371098 | ||
| Nonalcoholic Steatohepatitis Clinical Research Network | Q110296507 | ||
| Kris V. Kowdley | Q110296712 | ||
| P2093 | author name string | Naga Chalasani | |
| Xiuqing Guo | |||
| Rohit Loomba | |||
| Oscar W Cummings | |||
| Pallav Bhatnagar | |||
| Samer Gawrieh | |||
| Laura A Wilson | |||
| Katherine Yates | |||
| Sreekumar Pillai | |||
| Jingyi Tan | |||
| Marie Lauzon | |||
| P2860 | cites work | Population structure and eigenanalysis | Q21145248 |
| Mutations in ANO3 cause dominant craniocervical dystonia: ion channel implicated in pathogenesis | Q24602504 | ||
| Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis | Q24625697 | ||
| Principal components analysis corrects for stratification in genome-wide association studies | Q27860975 | ||
| Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial | Q28253122 | ||
| Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance | Q28255243 | ||
| Genome-wide association study identifies variants associated with histologic features of nonalcoholic Fatty liver disease | Q29417076 | ||
| HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin | Q29417159 | ||
| Design and validation of a histological scoring system for nonalcoholic fatty liver disease | Q29614930 | ||
| Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening | Q30277347 | ||
| Identification of pancreatic juice proteins as biomarkers of pancreatic cancer | Q33567893 | ||
| Genome-wide association study identifies loci influencing concentrations of liver enzymes in plasma | Q34224637 | ||
| Genome-wide association study of CSF levels of 59 alzheimer's disease candidate proteins: significant associations with proteins involved in amyloid processing and inflammation | Q34394932 | ||
| Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles | Q35085772 | ||
| Genetic polymorphism of cytochrome P450 4F2, vitamin E level and histological response in adults and children with nonalcoholic fatty liver disease who participated in PIVENS and TONIC clinical trials | Q35156042 | ||
| Genetic Analysis of Human Chymotrypsin-Like Elastases 3A and 3B (CELA3A and CELA3B) to Assess the Role of Complex Formation between Proelastases and Procarboxypeptidases in Chronic Pancreatitis | Q37534966 | ||
| Pharmacotherapy for Nonalcoholic Fatty Liver Disease | Q38588344 | ||
| Genome-Wide Association Studies in Drug-Induced Liver Injury: Step Change in Understanding the Pathogenesis | Q38671650 | ||
| Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. | Q38680300 | ||
| Pharmacogenomic and personalized approaches to tackle nonalcoholic fatty liver disease | Q38845334 | ||
| Hyperckemia and myalgia are common presentations of anoctamin-5-related myopathy in French patients | Q38967024 | ||
| Minocycline hepatotoxicity: Clinical characterization and identification of HLA-B∗35:02 as a risk factor. | Q40454552 | ||
| Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States | Q41626076 | ||
| Emerging Treatments for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis | Q47613871 | ||
| Gain of function of TMEM16E/ANO5 scrambling activity caused by a mutation associated with gnathodiaphyseal dysplasia | Q47620257 | ||
| Pharmacogenomics: Precision Medicine and Drug Response | Q47860317 | ||
| Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis | Q49797701 | ||
| Anoctamin5 regulates cell migration and invasion in thyroid cancer | Q50119969 | ||
| Detection of human elastase isoforms by the ScheBo Pancreatic Elastase 1 Test. | Q50939105 | ||
| Coding variants in PNPLA3 and TM6SF2 are risk factors for hepatic steatosis and elevated serum alanine aminotransferases caused by a glucagon receptor antagonist. | Q55032630 | ||
| The I148M Variant of PNPLA3 Reduces the Response to Docosahexaenoic Acid in Children with Non-Alcoholic Fatty Liver Disease | Q57659822 | ||
| Treating liver fat and serum triglyceride levels in NAFLD, effects of PNPLA3 and TM6SF2 genotypes: Results from the WELCOME trial | Q60408831 | ||
| A Genetic Score Associates With Pioglitazone Response in Patients With Non-alcoholic Steatohepatitis. | Q64912299 | ||
| Factors Associated With Histologic Response in Adult Patients With Nonalcoholic Steatohepatitis | Q91484128 | ||
| P433 | issue | 12 | |
| P304 | page(s) | 1571-1584 | |
| P577 | publication date | 2019-11-03 | |
| P1433 | published in | Hepatology Communications | Q50817751 |
| P1476 | title | A Pilot Genome-Wide Analysis Study Identifies Loci Associated With Response to Obeticholic Acid in Patients With NASH | |
| P478 | volume | 3 |
Search more.